Get it on Google Play

Alumis shares Phase 3 data on envudeucitinib for plaque psoriasis

October 9, 2026 4:00 AM EDT Send to a Friend
Alumis Inc. (Nasdaq: ALMS) presented new Phase 3 clinical data for its investigational drug envudeucitinib at the 26th Annual Fall ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login